Endopeptidase Therapy for Anti-Glomerular Basement Membrane Disease: Beware of Anti-Hinge Antibodies!

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY（2022）

引用 0|浏览4

暂无评分

摘要

We read with great interest the recent publication reporting an open-label phase 2a study of imlifidase (IdeS endoprotease) in severe anti–glomerular basement membrane (anti-GBM) disease.[1][1] IdeS specifically cleaves human IgG in the lower hinge region, producing an F(ab′)2 fragment and two

查看译文

关键词

anti-GBM disease, endopeptidase therapy, anti-hinge antibodies, imlifidase

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要